Barchart is a leading provider of market data and services to the global financial, media, and commodity industries. From our interactive charting library, through to our leading financial analysis desktops, we connect you to the content you need.
| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 2,475.60 +4.84% on 11/01/24 | | 2,717.70 -4.50% on 11/11/24 | +28.90 (+1.13%) since 10/18/24 |
| 3-Month | 2,398.20 +8.23% on 09/11/24 | | 2,717.70 -4.50% on 11/11/24 | +156.10 (+6.40%) since 08/20/24 |
| 52-Week | 2,117.80 +22.56% on 11/21/23 | | 2,717.70 -4.50% on 11/11/24 | +448.90 (+20.91%) since 11/20/23 |
Wall Street analysts expect the company to report earnings per share of $2.36 on revenue of $3.14 billion
The Chrome default is “a market reality that significantly narrows the available channels of distribution and thus disincentivizes the emergence of new competition,” DOJ lawyers said in a court filing....
Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will...
As Paychex has underperformed the broader market over the past year, analysts remain cautious about the stock’s prospects.
Retail sentiment on the stock rose to ‘extremely bullish’ (92/100) from ‘neutral’ (52/100) a week ago. Message volumes rose to ‘extremely high’ levels.
The rally in the world's largest cryptocurrency is showing no signs of slowdown since Donald Trump’s victory in the presidential election spurred excitement about the digital currency. Bitcoin surged...
Adobe ADBE shares have declined 19.4% in the trailing 12 months, underperforming the broader Zacks Computer & Technology sector’s return of 32.9% and the Zacks Computer Software industry’s appreciation...
Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...
Barkin also indicated that businesses are worried about a potential rise in inflation in the wake of President-elect Donald Trump’s potential policies on tariffs and mass deportations
Snowflake SNOW reported third-quarter fiscal 2025 non-GAAP earnings of 20 cents per share, beating the Zacks Consensus Estimate by 33.33%. The figure declined 20% year over year.SNOW’s earnings beat...
The Barchart Trading Guide is a Buy Signal with a Average Signal Strength.
| Symbol | Last | Change |
|---|---|---|
| QQZ24 | 2,595.50s | -3.10 |
| Russell 2000 Value | ||
| ESZ24 | 5,982.00 | +44.25 |
| S&P 500 E-Mini | ||
| NQZ24 | 20,864.25 | +115.25 |
| Nasdaq 100 E-Mini | ||
| YMZ24 | 44,122 | +606 |
| Dow Futures Mini | ||
| QRZ24 | 2,382.30 | +47.10 |
| Russell 2000 E-Mini | ||
| EWZ24 | 3,305.10 | +60.30 |
| S&P Midcap E-Mini | ||
| ETZ24 | 5,982.00 | +44.25 |
| S&P 500 Micro | ||
| NMZ24 | 20,865.00 | +116.00 |
| Nasdaq 100 Micro | ||
| VIZ24 | 16.8000 | -0.1522 |
| S&P 500 VIX | ||
| GDZ24 | 540.15s | +0.25 |
| S&P GSCI | ||
| AHZ24 | 98.72 | +0.22 |
| Bloom Commodity Index | ||
| 3rd Resistance Point | 2,595.50 |
| 2nd Resistance Point | 2,595.50 |
| 1st Resistance Point | 2,595.50 |
| Last Price | 2,595.50s |
| 1st Support Level | 2,595.50 |
| 2nd Support Level | 2,595.50 |
| 3rd Support Level | 2,595.50 |
| 52-Week High | 2,717.70 |
| Last Price | 2,595.50s |
| Fibonacci 61.8% | 2,488.54 |
| Fibonacci 50% | 2,417.75 |
| Fibonacci 38.2% | 2,346.96 |
| 52-Week Low | 2,117.80 |
